Sep 17, 2026, 13:58 UTC
Clearmind Medicine's Chief of Global Impact, Mary-Elizabeth Gifford, testified at a U.S. Food and Drug Administration hearing in Washington, D.C. on the potential future therapeutic use of psychedelic drugs, addressing patient access.
Source:Sep 17, 2026, 11:42 UTC
Clearmind Medicine delivered a briefing to the FDA after being invited to a psychedelic hearing in Washington, D.C., where its Chief of Global Impact Mary-Elizabeth Gifford spoke on patient access and shared insights from the company's clinical trial at Yale and Johns Hopkins.
Source:Sep 11, 2026, 12:00 UTC
Clearmind Medicine Inc. announced the enrollment of the first patients with Alcohol Use Disorder in its ongoing clinical trial evaluating CMND-100, its proprietary psychedelic-based treatment candidate for AUD.
Source:Sep 8, 2026, 11:42 UTC
Clearmind Medicine received Yale University IRB approval to initiate patient recruitment for Parts B and C of its Phase I/II clinical trial of CMND-100, following positive safety results.
Source:Sep 4, 2026, 11:32 UTC
CLEARMIND MEDICINE signed a definitive agreement to acquire a 51% stake in a wireless charging company focused on automated parking and robotaxis.
Sep 1, 2026, 11:37 UTC
Clearmind Medicine initiated Phase IIa of its Phase I/IIa clinical trial for CMND-100, a treatment for Alcohol Use Disorder, with six patients enrolled at two medical centers in Israel.
Source:Aug 24, 2026, 12:03 UTC
Clearmind Medicine announced the U.S. publication of a patent application covering MDMA-N-acylethanolamines for PTSD treatment, expanding IP from its collaboration with Neurothera Labs Inc.
Aug 13, 2026, 18:05 UTC
Clearmind Medicine's independent Data and Safety Monitoring Board approved advancing its Phase 1/2 clinical trial for alcohol addiction treatment on Thursday.
Source:Aug 6, 2026, 12:00 UTC
Clearmind Medicine announced that its independent Data and Safety Monitoring Board unanimously approved advancing its Phase I/II clinical trial of CMND-100 in Alcohol Use Disorder patients to parts B and C.
Source:Aug 3, 2026, 12:02 UTC
Clearmind Medicine Inc. announced on August 3, 2026 that it signed a non-binding Letter of Intent to acquire a 51% majority stake in an unnamed company specializing in EV wireless charging solutions for automated parking systems.
Source:Jul 30, 2026, 12:30 UTC
Clearmind Medicine announced positive safety results from Part A of its Phase I/II clinical trial for CMND-100, a drug candidate for Alcohol Use Disorder, showing consistent tolerability across all dose cohorts.
Source:Jul 20, 2026, 11:55 UTC
Clearmind Medicine filed a patent application with the Hong Kong Patent Office for novel psychedelic compounds targeting PTSD and other mental health disorders.
Source:Jul 16, 2026, 13:30 UTC
Clearmind Medicine announced positive ex vivo mucoadhesion results for its intranasal formulation of MEAI, a psychedelic-based neuroplastogen.
Source:Jul 7, 2026, 11:42 UTC
Clearmind Medicine Inc. announced successful formulation feasibility study supporting potential new intranasal delivery route for its proprietary MEAI compound for alcohol use disorder treatment.
Source:Jul 6, 2026, 19:53 UTC
Clearmind Medicine received a new U.S. patent for binge behavior treatments, strengthening its IP portfolio.
Source:Jun 16, 2026, 11:52 UTC
Clearmind Medicine completed dosing for all 24 participants in Part A of its Phase I/II clinical trial for CMND-100, a drug candidate for Alcohol Use Disorder.